Illumina Director Daniel Bradbury Sells 2,100 Shares (ILMN)
Illumina (NASDAQ:ILMN) Director Daniel Bradbury sold 2,100 shares of Illumina stock on the open market in a transaction dated Monday, August 4th. The stock was sold at an average price of $159.77, for a total value of $335,517.00. Following the completion of the sale, the director now directly owns 12,466 shares of the company’s stock, valued at approximately $1,991,693. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
ILMN has been the subject of a number of recent research reports. Analysts at Tigress Financial initiated coverage on shares of Illumina in a research note on Friday. They set a “buy” rating on the stock. Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of Illumina in a research note on Thursday, July 24th. They now have a $198.00 price target on the stock, up previously from $180.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Illumina in a research note on Thursday, July 24th. They now have a $230.00 price target on the stock, up previously from $190.00. Six analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Illumina has a consensus rating of “Buy” and an average target price of $170.58.
Shares of Illumina (NASDAQ:ILMN) traded up 0.52% during mid-day trading on Monday, hitting $161.71. The stock had a trading volume of 939,498 shares. Illumina has a 1-year low of $72.77 and a 1-year high of $185.00. The stock’s 50-day moving average is $172.2 and its 200-day moving average is $158.7. The company has a market cap of $21.116 billion and a price-to-earnings ratio of 107.46.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $0.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter last year, the company posted $0.43 earnings per share. Illumina’s revenue was up 29.5% compared to the same quarter last year. On average, analysts predict that Illumina will post $2.29 earnings per share for the current fiscal year.
Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.